194 related articles for article (PubMed ID: 30353028)
1. Analysis of the relationship between the KRAS G12V oncogene and the Hippo effector YAP1 in embryonal rhabdomyosarcoma.
Mohamed AD; Shah N; Hettmer S; Vargesson N; Wackerhage H
Sci Rep; 2018 Oct; 8(1):15674. PubMed ID: 30353028
[TBL] [Abstract][Full Text] [Related]
2. The Hippo effector TAZ (WWTR1) transforms myoblasts and TAZ abundance is associated with reduced survival in embryonal rhabdomyosarcoma.
Mohamed A; Sun C; De Mello V; Selfe J; Missiaglia E; Shipley J; Murray GI; Zammit PS; Wackerhage H
J Pathol; 2016 Sep; 240(1):3-14. PubMed ID: 27184927
[TBL] [Abstract][Full Text] [Related]
3. The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formation.
Tremblay AM; Missiaglia E; Galli GG; Hettmer S; Urcia R; Carrara M; Judson RN; Thway K; Nadal G; Selfe JL; Murray G; Calogero RA; De Bari C; Zammit PS; Delorenzi M; Wagers AJ; Shipley J; Wackerhage H; Camargo FD
Cancer Cell; 2014 Aug; 26(2):273-87. PubMed ID: 25087979
[TBL] [Abstract][Full Text] [Related]
4. OTUB2 Promotes Cancer Metastasis via Hippo-Independent Activation of YAP and TAZ.
Zhang Z; Du J; Wang S; Shao L; Jin K; Li F; Wei B; Ding W; Fu P; van Dam H; Wang A; Jin J; Ding C; Yang B; Zheng M; Feng XH; Guan KL; Zhang L
Mol Cell; 2019 Jan; 73(1):7-21.e7. PubMed ID: 30472188
[TBL] [Abstract][Full Text] [Related]
5. Role of the YAP Oncoprotein in Priming Ras-Driven Rhabdomyosarcoma.
Slemmons KK; Crose LE; Rudzinski E; Bentley RC; Linardic CM
PLoS One; 2015; 10(10):e0140781. PubMed ID: 26496700
[TBL] [Abstract][Full Text] [Related]
6. Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development.
Rozengurt E; Eibl G
World J Gastroenterol; 2019 Apr; 25(15):1797-1816. PubMed ID: 31057295
[TBL] [Abstract][Full Text] [Related]
7. KRAS and YAP1 converge to regulate EMT and tumor survival.
Shao DD; Xue W; Krall EB; Bhutkar A; Piccioni F; Wang X; Schinzel AC; Sood S; Rosenbluh J; Kim JW; Zwang Y; Roberts TM; Root DE; Jacks T; Hahn WC
Cell; 2014 Jul; 158(1):171-84. PubMed ID: 24954536
[TBL] [Abstract][Full Text] [Related]
8. A Novel Notch-YAP Circuit Drives Stemness and Tumorigenesis in Embryonal Rhabdomyosarcoma.
Slemmons KK; Crose LES; Riedel S; Sushnitha M; Belyea B; Linardic CM
Mol Cancer Res; 2017 Dec; 15(12):1777-1791. PubMed ID: 28923841
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity.
Rao G; Kim IK; Conforti F; Liu J; Zhang YW; Giaccone G
Eur J Cancer; 2018 Aug; 99():37-48. PubMed ID: 29902613
[TBL] [Abstract][Full Text] [Related]
10. Notch1 Deficiency Induces Tumor Cell Accumulation Inside the Bronchiolar Lumen and Increases TAZ Expression in an Autochthonous
Meder L; Florin A; Ozretić L; Nill M; Koker M; Meemboor S; Radtke F; Diehl L; Ullrich RT; Odenthal M; Büttner R; Heukamp LC
Pathol Oncol Res; 2021; 27():596522. PubMed ID: 34257546
[No Abstract] [Full Text] [Related]
11. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
[TBL] [Abstract][Full Text] [Related]
12. TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors.
Edwards AC; Stalnecker CA; Jean Morales A; Taylor KE; Klomp JE; Klomp JA; Waters AM; Sudhakar N; Hallin J; Tang TT; Olson P; Post L; Christensen JG; Cox AD; Der CJ
Cancer Res; 2023 Dec; 83(24):4112-4129. PubMed ID: 37934103
[TBL] [Abstract][Full Text] [Related]
13. GNAS
Ideno N; Yamaguchi H; Ghosh B; Gupta S; Okumura T; Steffen DJ; Fisher CG; Wood LD; Singhi AD; Nakamura M; Gutkind JS; Maitra A
Gastroenterology; 2018 Nov; 155(5):1593-1607.e12. PubMed ID: 30142336
[TBL] [Abstract][Full Text] [Related]
14. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
[TBL] [Abstract][Full Text] [Related]
15. Yap is a novel regulator of C2C12 myogenesis.
Watt KI; Judson R; Medlow P; Reid K; Kurth TB; Burniston JG; Ratkevicius A; De Bari C; Wackerhage H
Biochem Biophys Res Commun; 2010 Mar; 393(4):619-24. PubMed ID: 20153295
[TBL] [Abstract][Full Text] [Related]
16. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity.
Shimomura T; Miyamura N; Hata S; Miura R; Hirayama J; Nishina H
Biochem Biophys Res Commun; 2014 Jan; 443(3):917-23. PubMed ID: 24380865
[TBL] [Abstract][Full Text] [Related]
17. Mu-KRAS attenuates Hippo signaling pathway through PKCι to sustain the growth of pancreatic cancer.
Wang P; Zhang H; Yang J; Li Z; Wang Y; Leng X; Ganapathy S; Isakson P; Chen C; Zhu T
J Cell Physiol; 2020 Jan; 235(1):408-420. PubMed ID: 31230347
[TBL] [Abstract][Full Text] [Related]
18. YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling.
Coggins GE; Farrel A; Rathi KS; Hayes CM; Scolaro L; Rokita JL; Maris JM
Cancer Res; 2019 Dec; 79(24):6204-6214. PubMed ID: 31672841
[TBL] [Abstract][Full Text] [Related]
19. Targeting Hippo-Dependent and Hippo-Independent YAP1 Signaling for the Treatment of Childhood Rhabdomyosarcoma.
Slemmons KK; Yeung C; Baumgart JT; Juarez JOM; McCalla A; Helman LJ
Cancer Res; 2020 Jul; 80(14):3046-3056. PubMed ID: 32354737
[TBL] [Abstract][Full Text] [Related]
20. Initiation of human mammary cell tumorigenesis by mutant KRAS requires YAP inactivation.
Lefort S; Tan S; Balani S; Rafn B; Pellacani D; Hirst M; Sorensen PH; Eaves CJ
Oncogene; 2020 Feb; 39(9):1957-1968. PubMed ID: 31772328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]